1. Home
  2. Analysis
  3. Flexeril
  4. Kadcyla

Flexeril and Kadcyla drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported only by a few people who take Flexeril and Kadcyla together.

The phase IV clinical study analyzes what interactions people who take Flexeril and Kadcyla have. It is created by eHealthMe based on reports of 5 people who take the same drugs from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 07, 2023

5 people who take Flexeril and Kadcyla together, and have interactions are studied.

What is Flexeril?

Flexeril has active ingredients of cyclobenzaprine hydrochloride. It is often used in muscle spasms. eHealthMe is studying from 36,890 Flexeril users for its effectiveness, alternative drugs and more.

What is Kadcyla?

Kadcyla has active ingredients of ado-trastuzumab emtansine. eHealthMe is studying from 4,502 Kadcyla users for its effectiveness, alternative drugs and more.

Number of Flexeril and Kadcyla reports submitted per year:

Flexeril and Kadcyla drug interactions.

Common Flexeril and Kadcyla drug interactions by gender *:

female:

  1. Anaemia
  2. Depression
  3. Epistaxis
  4. Food intolerance
  5. Malaise
  6. Metastases to central nervous system
  7. Metastases to liver
  8. Neuropathy peripheral
  9. Palmar-plantar erythrodysaesthesia syndrome
  10. Peripheral swelling

male:

n/a

Common Flexeril and Kadcyla drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Abdominal pain
  2. Anaemia
  3. Malaise
  4. Metastases to central nervous system
  5. Metastases to liver
  6. Neuropathy peripheral
  7. Neutropenia
  8. Pain
  9. Palmar-plantar erythrodysaesthesia syndrome
  10. Peripheral swelling

50-59:

n/a

60+:

n/a

* Approximation only. Some reports may have incomplete information.

Do you take Flexeril and Kadcyla?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Flexeril and Kadcyla:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Flexeril side effects:

Browse all side effects of Flexeril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Kadcyla side effects:

Browse all side effects of Kadcyla:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Flexeril interactions:

Browse all interactions between Flexeril and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Kadcyla interactions:

Browse all interactions between Kadcyla and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on cyclobenzaprine hydrochloride and ado-trastuzumab emtansine (the active ingredients of Flexeril and Kadcyla, respectively), and Flexeril and Kadcyla (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Flexeril and Kadcyla.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.